PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes

被引:17
作者
Lattanzio, Rossano [1 ,2 ]
Iezzi, Manuela [2 ,3 ]
Sala, Gianluca [1 ,2 ]
Tinari, Nicola [1 ,2 ]
Falasca, Marco [4 ]
Alberti, Saverio [5 ]
Buglioni, Simonetta [6 ]
Mottolese, Marcella [6 ]
Perracchio, Letizia [6 ]
Natali, Pier Giorgio [2 ]
Piantelli, Mauro [2 ]
机构
[1] G dAnnunzio Univ Chieti Pescara, Dept Med Oral & Biotechnol Sci, Chieti, Italy
[2] G dAnnunzio Univ Chieti Pescara, CAST, Via Luigi Polacchi 11, I-66100 Chieti, Italy
[3] G dAnnunzio Univ Chieti Pescara, Dept Med & Aging Sci, Chieti, Italy
[4] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm & Biomed Sci, Metab Signalling Grp, Perth, Australia
[5] Univ Messina, Dept Biotechnol BIOMORF, Via Consolare Valeria 1, I-98125 Messina, Italy
[6] Regina Elena Inst Canc Res, Dept Pathol, Via E Chianesi 53, I-00144 Rome, Italy
关键词
Breast cancer; Phospholipase C gamma 1; Prognosis; Luminal subtypes; Menopausal status; INTERNATIONAL EXPERT CONSENSUS; UNFOLDED PROTEIN RESPONSE; PHOSPHOLIPASE C-GAMMA-1; ESTROGEN-RECEPTOR; PRIMARY THERAPY; CYTOSKELETON; HIGHLIGHTS; SURVIVAL;
D O I
10.1186/s12885-019-5949-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundPhospholipase C gamma 1 (PLC gamma 1) is highly expressed in human tumours. Our previous studies reported that both stable and inducible PLC gamma 1 down-regulation can inhibit formation of breast-cancer-derived experimental lung metastasis. Further, high expression of PLC gamma 1 and its constitutively activated forms (i.e., PLC gamma 1-pY1253, PLC gamma 1-pY783) is associated with worse clinical outcome in terms of incidence of distant metastases, but not of local relapse in T1-T2, N0 breast cancer patients.MethodsIn the present retrospective study, we analysed the prognostic role of PLC gamma 1 in early breast cancer patients stratified according to the St. Gallen criteria and to their menopausal status. PLC gamma 1-pY1253 and PLC gamma 1-pY783 protein expression levels were determined by immunohistochemistry on tissue microarrays, and were correlated with patients' clinical data, using univariate and multivariate statistical analyses.ResultsIn our series, the prognostic value of PLC gamma 1 overexpression was restricted to Luminal type tumours. From multivariate analyses, pY1253-PLC gamma 1(High) was an independent prognostic factor only in postmenopausal patients with Luminal-B tumours (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.1-5.3; P=0.034). Conversely, PLC gamma 1-pY783(High) was a remarkably strong risk factor (HR, 20.1; 95% CI, 2.2-178.4; P=0.003) for pre/perimenopausal patients with Luminal-A tumours.ConclusionsPLC gamma 1 overexpression is a strong predictive surrogate marker of development of metastases in early Luminal-A and -B breast cancer patients, being able to discriminate patients with high and low risk of metastases. Therefore, targeting the PLC gamma 1 pathway can be considered of potential benefit for prevention of metastatic disease.
引用
收藏
页数:10
相关论文
共 50 条
[31]   Prognostic impact of surgery for early-stage invasive breast cancer on breast cancer-specific survival, overall survival, and recurrence risk: a population-based analysis [J].
Thoene, Kathrin ;
Rudolph, Anja ;
Obi, Nadia ;
Chang-Claude, Jenny ;
Flesch-Janys, Dieter .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (02) :381-390
[32]   Prognostic impact of surgery for early-stage invasive breast cancer on breast cancer-specific survival, overall survival, and recurrence risk: a population-based analysis [J].
Kathrin Thöne ;
Anja Rudolph ;
Nadia Obi ;
Jenny Chang-Claude ;
Dieter Flesch-Janys .
Breast Cancer Research and Treatment, 2018, 170 :381-390
[33]   Trait anxiety predicts disease-specific health status in early-stage breast cancer patients [J].
Van Esch, Lotje ;
Roukema, Jan A. ;
Van der Steeg, Alida F. W. ;
De Vries, Jolanda .
QUALITY OF LIFE RESEARCH, 2011, 20 (06) :865-873
[34]   Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer [J].
Park, In Hae ;
Kong, Sun-Young ;
Ro, Jae Yoon ;
Kwon, Youngmee ;
Kang, Joo Hyun ;
Mo, Hye Jin ;
Jung, So-Youn ;
Lee, Seeyoun ;
Lee, Keun Seok ;
Kang, Han-Sung ;
Lee, Eunsook ;
Joo, Jungnam ;
Ro, Jungsil .
CLINICAL BREAST CANCER, 2016, 16 (01) :51-58
[35]   Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression [J].
Sharon Hensley Alford ;
Katherine Toy ;
Sofia D. Merajver ;
Celina G. Kleer .
Breast Cancer Research and Treatment, 2012, 132 :429-437
[36]   Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression [J].
Alford, Sharon Hensley ;
Toy, Katherine ;
Merajver, Sofia D. ;
Kleer, Celina G. .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) :429-437
[37]   International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer [J].
Lin, Nancy U. ;
Thomssen, Christoph ;
Cardoso, Fatima ;
Cameron, David ;
Cufer, Tanja ;
Fallowfield, Lesley ;
Francis, Prudence A. ;
Kyriakides, Stella ;
Pagani, Olivia ;
Senkus, Elzbieta ;
Costa, Alberto ;
Winer, Eric P. .
BREAST, 2013, 22 (03) :203-210
[38]   Does Compliance with Radiation Therapy Differ in African-American Patients with Early-Stage Breast Cancer?1 [J].
Sharma, Charu ;
Harris, Lyndsay ;
Haffty, Bruce G. ;
Yang, Qifeng ;
Moran, Meena S. .
BREAST JOURNAL, 2010, 16 (02) :193-196
[39]   Mastectomy, HER2 Receptor Positivity, NPI, Late Stage and Luminal B-Type Tumor as Poor Prognostic Factors in Geriatric Patients with Breast Cancer [J].
Nak, Demet ;
Kivrak, Mehmet .
DIAGNOSTICS, 2025, 15 (01)
[40]   Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes [J].
Pavanelli, Ana Carolina ;
Mangone, Flavia Rotea ;
Yoganathan, Piriya ;
Bessa, Simone Aparecida ;
Nonogaki, Suely ;
de Toledo Osorio, Cynthia A. B. ;
de Andrade, Victor Piana ;
Soares, Ibere Cauduro ;
de Mello, Evandro Sobrosa ;
Mulligan, Lois M. ;
Nagai, Maria Aparecida .
BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (01) :43-52